NRX Pharmaceuticals, Inc. (NRXP)
Health Care · Biotechnology · NASDAQ
A clinical-stage biopharmaceutical company developing NMDA-modulating neuroplasticity drugs for severe CNS disorders while operating an interventional psychiatric clinic network.
What NRX Pharmaceuticals, Inc. does
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, including suicidal depression, chronic pain, PTSD, and schizophrenia, primarily by modulating the NMDA receptor. Through its HOPE Therapeutics subsidiary, the company also operates interventional psychiatry clinics providing treatments such as ketamine infusions, TMS, and digital therapeutics. The company has recently expanded its scope to include monoclonal antibodies for neurodegenerative and metabolic diseases through its GeNeuro subsidiary.
Recent developments
NRx recently raised $22.3 million in a public offering and was selected as a prime contractor for a DARPA-funded clinical trial (SPARC-TMS) to study NRX-101 in combination with robotic TMS. Additionally, the company acquired clinical-stage monoclonal antibody assets for ALS, MS, and Type 1 Diabetes through its new subsidiary, GeNeuro, Inc.
From NRX Pharmaceuticals, Inc.'s filing of 2026-08-17.
Themes: neuropsychiatry, suicidal depression treatment, NMDA receptor modulation, interventional psychiatry, neurodegenerative disease research, military medical research
Fundamentals
- Price$2.62 as of 2026-10-20 close
- Market cap$113M as of 2026-08-14 (share count; price 2026-10-20)
- 1-year return-20.8% 2025-10-20 close $3.31 → 2026-10-20 close $2.62
- P/En/a negative earnings
- Net margin-2336.5% FY2025, SEC XBRL
- ROICn/a No figure: its 10-K tags no pre-tax income, so no tax rate can be taken.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta1.07 as of 2026-09-03
- Last reported earnings2026-08-17 SEC EDGAR Form 8-K (Item 2.02)
How NRXP compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-03
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $1M | -$7M | -$17M | -$9M† | — |
| Q1 FY2026 2026-03-31 | $1M | -$5M | -$1M | -$4M | — |
| Q4 FY2025 2025-12-31 | $983000† | -$5M† | $360000† | -$4M† | — |
| Q3 FY2025 2025-09-30 | $242000 | -$4M | -$6M | -$3M† | — |
| Q2 FY2025 2025-06-30 | $0 | -$4M | -$18M | -$4M† | — |
| Q1 FY2025 2025-03-31 | $0 | -$4M | -$6M | -$3M | $0 |
| Q4 FY2024 2024-12-31 | — | -$2M† | -$9M† | -$2M† | $0† |
| Q3 FY2024 2024-09-30 | $0 | -$3M | -$2M | -$2M† | $0† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$27M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How NRX Pharmaceuticals, Inc. looks technically
NRX Pharmaceuticals, Inc. (NRXP) is trading 10.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 102 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 32, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 5 trading days ago. It is 48.2% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 10.6% below its 200-day average, the long-term trend line — a long-term downtrend | -10.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.19 | $3.19 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.93 | $2.93 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 3.09. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 102 trading days ago — a "golden cross", a bullish long-term signal | 102 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with sellers in control | 30.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 32, neither overbought (above 70) nor oversold (below 30) | 32.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($2.48 to $3.00) — its "stochastic" reading is 27 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 26.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 25 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.05 | $5.05 |
|---|---|---|
| From the 52-week high | it is 48.2% below its 52-week high (its highest price of the past year) | -48.2% |
| Above the 52-week low | it is 61.7% above its 52-week low (its lowest price of the past year) | +61.7% |
| Below the 52-week high | it is 48.2% below its highest point of the past year | 48.2% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $769.90 (set on 2020-12-22) | $769.90 |
| Given back of the 52-week move | over the past year its closes ranged ($1.68 to $4.62), and it has given back well over two thirds of its rise from last year’s low — 68% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.71 to $2.80. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 68.0% |
| From the all-time high | it is 99.7% below its all-time high | -99.7% |
| Nearest price level | it is trading 5.5% below a resistance level at $2.76 — a price it turned at three times since 2026-01-02, most recently on 2026-10-05. Since 2024-10-21 it has 5 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +5.5% |
| All-time low | its lowest closing price on record is $1.10 (set on 2024-10-16) | $1.10 |
| Above the all-time low | it is 138.2% above its all-time low | +138.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 72% of it) | 28th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.168 between its high and its low — about 6.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.168 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.54 and $3.14 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.54 – $2.84 – $3.14 |
| Typical daily range (% of price) | its price moves about 6.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.4% |
| Stretch from the 200-day average | it is trading 1.9 daily ranges below its 200-day average price (10.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.9 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.90× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
| Since a bearish engulfing | 7 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 7 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-20 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 2.0% below the previous close 9 sessions ago and has not traded back through the level it left behind at 2.94 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.0% |
| Gap filled | a 7.5% gap up opened on 2026-10-19 has been "filled" today — price traded back through the level the gap left behind, and it took 1 session to close | today |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 22.1 percentage points (the stock lost 21.1% while the market gained 1.0%) | -22.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 41.0 percentage points (the stock lost 37.3% while the market gained 3.6%) | -41.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 26.6 percentage points (the stock lost 18.1% while the market gained 8.5%) | -26.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 35.4 percentage points (the stock lost 20.8% while the market gained 14.6%) | -35.4% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 26% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 7.2% of the share price. | -26.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 13% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $3.01 — a volume-weighted average of daily closes over 195 sessions, not a true tick-by-tick VWAP. | -12.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 17% below the average price paid since it last reported on 2026-08-14 (its 10-Q), so the typical buyer over that stretch is under water. That average is $3.17 — a volume-weighted average of daily closes over 47 sessions, not a true tick-by-tick VWAP. | -17.2% |
Price levels it has turned at before
NRXP last closed at $2.62 on 2026-10-20. Since 2024-10-21 it has turned at 5 prices below its last close and 10 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.76 | Resistance | 5.5% above the last close | turned there three times · 2026-01-02 to 2026-10-05 |
| $2.81 | Resistance | 7.4% above the last close | turned there three times · 2025-09-23 to 2026-07-30 |
| $2.42 | Support | 7.4% below the last close | turned there twice · 2025-03-17 to 2025-11-07 |
| $2.88 | Resistance | 10.1% above the last close | turned there three times · 2025-06-23 to 2026-05-20 |
| $2.25 | Support | 14.3% below the last close | turned there twice · 2025-08-29 to 2026-03-16 |
| $2.14 | Support | 18.3% below the last close | turned there twice · 2025-04-14 to 2025-05-05 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $3.09.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $3.00 and $3.09 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 6 trading days, since 2026-10-13.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · lagging the market · Printed a doji candle · Just filled a gap (5%+ closed in the last week) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$38.50 range $10.00 – $50.00; median $47.00
Analyst estimates, as of 2026-10-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NRXP
- Consensus EPS estimate-$0.15 next reporting period, as of 2026-10-18
- Estimate change, 30 days-$0.07 from -$0.08, on 2026-09-13, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of losses and significant accumulated deficit with no guarantee of achieving future profitability.","Significant dependence on successful regulatory approvals for lead drug candidates (NRX-100, NRX-101, KETAFREE).","Requirement for additional capital to support ongoing clinical trials and commercialization activities."]
What changed in the latest 10-Q
AI-assisted comparison of NRXP's 10-Q filed 2026-05-15 against the prior one filed 2025-11-14.
Management's Discussion & Analysis (MD&A)
- Added:
- In Spring 2026, NRx founded two additional Florida-based subsidiaries: NRx Defense Systems, Inc. (NDS) and GeNeuro, Inc. (GeNeuro) (newer filing 2026-05-15)
- NDS is focused on advancing clinical findings that low-dose D-cycloserine may increase antidepressant and anti-suicidal effects of TMS by more than two-fold (newer filing 2026-05-15)
- GeNeuro is expected to focus on diagnostics and therapeutics related to Human Endogenous Retroviruses in Central Nervous System Diseases including Schizophrenia, Multiple Sclerosis, ALS, Autism, and Optic Neuritis (newer filing 2026-05-15)
- GeNeuro is partnered with the US National Institutes of Health through a CRADA with Fondation FondaMental (Paris) (newer filing 2026-05-15)
- A generic preservative-free formulation of ketamine (KETAFREE™) is now listed as a lead drug candidate (newer filing 2026-05-15)
- ANDA for KETAFREE™ was filed with priority review requested in September 2025 (newer filing 2026-05-15)
- Company received Discipline Review Letters from FDA Office of Generic Drugs related to labeling, bioequivalence, and drug product identifying no major deficiencies (newer filing 2026-05-15)
- In April 2026, Company met with FDA Office of Generic Drug Products leadership; FDA advised of endeavor to complete review by Summer 2026 (newer filing 2026-05-15)
- FDA inspected Company's manufacturing site and advised status was 'VAI' (newer filing 2026-05-15)
- Company has more than two years of real-time and accelerated stability data for blow-fill-seal presentation (newer filing 2026-05-15)
- Company arranged with manufacturer to initiate large scale commercial production at million unit per batch level (newer filing 2026-05-15)
- Company has manufactured three reference batches of KETAFREE™ and demonstrated room temperature shelf stability anticipated to support three-year shelf life (newer filing 2026-05-15)
- Management believes generic ketamine market exceeds $750 million per year (newer filing 2026-05-15)
- NDA for NRX-100 is expected to be filed during Q2 2026 (newer filing 2026-05-15)
- Company has amassed clinical trial evidence in more than 1,000 patients demonstrating ketamine efficacy (newer filing 2026-05-15)
- Company identified Real World Evidence from more than 65,000 US patients treated with ketamine (newer filing 2026-05-15)
- FDA agreed in writing to review Real World Evidence as part of NRX-100 New Drug Approval process (newer filing 2026-05-15)
- Company submitted RWE analysis plan to FDA prior to data analysis and submission (newer filing 2026-05-15)
- On April 18, 2026, President signed Executive Order 'Accelerating Medical Treatments for Serious Mental Illness' (newer filing 2026-05-15)
- Executive Order Section 4 emphasizes FDA consideration of real world evidence and data from HHS and Veterans Affairs on psychedelic drugs (newer filing 2026-05-15)
- US House 2026 Appropriations language guides FDA to use Real World Evidence for 'Substantial Evidence of Effectiveness' in approving products for suicidal depression and PTSD (newer filing 2026-05-15)
- Reference to congressional website and link provided for informational purposes only, not incorporated into 10-Q (newer filing 2026-05-15)
- Current market for ketamine labeled for depression treatment served only by nasal S-ketamine (SPRAVATO®) with estimated sales of approximately $2 billion per year (newer filing 2026-05-15)
- Company completed manufacture of three registration batches and demonstrated room temperature shelf stability for three-year shelf life (newer filing 2026-05-15)
- Removed:
- Older filing states 'All of our current drug development activities are focused on drugs that enhance neuroplasticity by modulating NMDA receptor' (older filing 2025-11-14)
- Older filing listed 'The Company has two lead drug candidates – NRX-100 and NRX-101' without mention of KETAFREE™ as a lead candidate (older filing 2025-11-14)
- ANDA for NRX-100 was filed during third quarter of 2025 (older filing 2025-11-14)
- After FDA meeting in August 2025, Company re-filed the ANDA (older filing 2025-11-14)
- On November 6, 2025, Company received FDA communication indicating no significant deficiencies (older filing 2025-11-14)
- Company aimed to launch KETAFREE™ in Q1 2026 (older filing 2025-11-14)
- NDA for NRX-100 was expected to be completed in fourth quarter 2025 (older filing 2025-11-14)
- NRX-100 was awarded Fast Track Designation by FDA (older filing 2025-11-14)
- Real World Efficacy Data to be drawn from 65,000 patients treated with IV ketamine compared to 6,000 patients treated with intranasal S-ketamine (older filing 2025-11-14)
- Interim analysis from first 20,000 patients suggested IV ketamine may have more rapid onset than nasal S-ketamine (older filing 2025-11-14)
- Company applied to receive Commissioner's National Priority Voucher (older filing 2025-11-14)
- In third quarter, Company was made aware of findings on low-dose D-cycloserine and TMS effects (older filing 2025-11-14)
- Company filed protocol with FDA to test low-dose NRX-101 in conjunction with ONE-D TMS protocol (older filing 2025-11-14)
- Success in clinical trial could lead to 2027 PDUFA date for TMS indication (older filing 2025-11-14)
- Discussion of HOPE Therapeutics incorporation in February 2024 (older filing 2025-11-14)
- December 2, 2024 formation of HTX Management Company, LLC subsidiary (older filing 2025-11-14)
- September 8, 2025 acquisition of Dura Medical, LLC (older filing 2025-11-14)
- November 10, 2025 announcement of HOPE's completion of clinical training on Ampa Health TMS device (older filing 2025-11-14)
- Reworded:
- Older: 'condensed consolidated financial statements' changed to 'consolidated financial statements' in newer filing (2026-05-15)
- Older: 'will distribute' changed to 'expects to distribute' regarding NeuroRx operations (2026-05-15)
- Older: '(NeuroRx)' with different parenthetical formatting changed in newer (2026-05-15)
- Older: 'All of our current drug development activities' changed to 'Historically, our drug development activities' reflecting shift to broader portfolio (2026-05-15)
- Older: Noted NRX-100 as ANDA filing, newer filing clarifies KETAFREE™ as the ANDA and NRX-100 as a different NDA formulation (2026-05-15)
- Notes:
- Newer filing text appears to truncate mid-sentence at point 3 regarding NRX-101, limiting complete comparison of that section
- Older filing also appears truncated at the end regarding HOPE operations, limiting full comparison of that section
- Congressional website reference in newer filing explicitly states information is 'not incorporated into this Quarterly Report on Form 10-Q' and provided 'for reference purposes only'
- Comparison focuses on explicitly stated changes; strategic/organizational implications are not assessed
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
Most recent open-market transaction: 2024-12-17. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NRXP's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding NRXP as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 2,237,030
- Reported value $9,149,453
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 3 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about NRXP's institutional holders → See what each manager we track holds →
Short interest (FINRA)
NRXP had 9,793,940 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
NRXP had 22.6% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 13.98 days to cover at the same settlement.
- Reported short interest (shares) 9,793,940
- Short interest (% of shares outstanding) 22.6%
- Prior settlement (shares) 9,773,562
- Reported change 0.21%
- Days to cover (reported) 13.98
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Janssen Pharmaceuticals (JNJ)
- Axsome Therapeutics (AXSM)
- Sage Therapeutics
- Biohaven (BHVN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NRXP vs…
Frequently asked questions
What does NRX Pharmaceuticals, Inc. (NRXP) do?
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, including suicidal depression, chronic pain, PTSD, and schizophrenia, primarily by modulating the NMDA receptor. Through its HOPE Therapeutics subsidiary, the company also operates interventional psychiatry clinics providing treatments such as ketamine infusions, TMS, and digital therapeutics.
What sector is NRX Pharmaceuticals, Inc. (NRXP) in?
NRX Pharmaceuticals, Inc. (NRXP) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are NRX Pharmaceuticals, Inc.'s (NRXP) competitors?
Notable peers of NRX Pharmaceuticals, Inc. (NRXP) include Janssen Pharmaceuticals, Axsome Therapeutics, Sage Therapeutics and Biohaven. This peer set is informational only — not financial advice.
Is NRX Pharmaceuticals, Inc. (NRXP) overbought or oversold right now?
NRX Pharmaceuticals, Inc. (NRXP) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 32, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NRXP come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.